Core Viewpoint - 10x Genomics is experiencing a positive momentum driven by AI-driven demand and improving execution and profitability trends [1][2]. Group 1: Financial Performance - 10x Genomics reported a fourth-quarter loss of 13 cents per share, which was better than the Wall Street expectation of a 20 cents loss [2]. - Sales for the fourth quarter reached $166.03 million, surpassing the consensus estimate of $159.27 million [2]. - The company forecasts fiscal 2026 sales between $600 million and $625 million, compared to the consensus of $611.58 million [3]. Group 2: AI and Growth Potential - AI-related projects currently represent a small percentage of revenue but are expected to become a significant growth vertical as demand for high-quality biological datasets increases [4]. - The launch of the Spatial Tissue Embedding Learning Atlas (STELA) by Bioptimus, in partnership with 10x Genomics, is seen as a validation of the Xenium spatial transcriptomics platform [5]. - The STELA initiative aims to profile up to 100,000 patient tissue specimens, highlighting the potential for AI-scale spatial data generation [5]. Group 3: Market Activity - 10x Genomics shares increased by 4.49% to $20.70 at the time of publication [5].